MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

United Therapeutics Corp

Затворен

СекторЗдравеопазване

312.14 1.91

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

299.98

Максимум

312.82

Ключови измерители

By Trading Economics

Приходи

-7.8M

301M

Продажби

-13M

736M

P/E

Средно за сектора

12.506

63.778

EPS

6.19

Марж на печалбата

40.943

Служители

1,305

EBITDA

6.3M

424M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+23.18% upside

Дивиденти

By Dow Jones

Следващи печалби

30.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-2.7B

14B

Предишно отваряне

310.23

Предишно затваряне

312.14

Настроения в новините

By Acuity

7%

93%

3 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

United Therapeutics Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.10.2024 г., 15:14 ч. UTC

Значими двигатели на пазара

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28.01.2025 г., 10:30 ч. UTC

Топ новини

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Сравнение с други в отрасъла

Ценова промяна

United Therapeutics Corp Прогноза

Ценова цел

By TipRanks

23.18% нагоре

12-месечна прогноза

Среден 384.64 USD  23.18%

Висок 460 USD

Нисък 293 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за United Therapeutics Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

12 ratings

8

Купи

3

Задържане

1

Продай

Техническа оценка

By Trading Central

307.64 / 312.61Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

3 / 386 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.